Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
The study was a multi-center, single-arm, prospective, non-interventional observational study in postmenopausal women with osteoporosis who had been treated with Prolia® for osteoporosis in routine clinical practice.
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Enrollment within 4 weeks following administration of the first Prolia® (denosumab 60 mg) injection
Received Prolia® subcutaneously for treatment of osteoporosis consistent with local (US/Canada) product label
You may not be if
Participation in ongoing or previous denosumab clinical trials
Currently enrolled in another investigational device or drug study, or less than 6 months since ending another investigational device or drug study(s), or receiving other investigational agent(s)
Contra-indicated for treatment with Prolia® according to the approved applicable local product label (US/Canada)
Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
